GSK plcGSK
NYSE • Healthcare
$50.99
P/E
14.91
PEG
2.13
FCF Yield
—
Rev Growth YoY
+1.5% YoY
Gross Margin
75.4%
Health Score
7/10
D/E Ratio
1.08
Confidence
MEDIUM
Business Snapshot
GSK plc is a global pharmaceuticals company focused on vaccines, specialty medicines, and general medicines. It operates as a major player in the drug manufacturing industry with a wide geographic footprint and blockbuster products in respiratory health, HIV, and infectious diseases. With TTM revenue of $32.78 billion, GSK sits in the large-cap tier. The company distinguishes itself through a strong vaccine portfolio (including shingles and RSV) and a deep pipeline that provides a regulatory moat around its patent-protected products.
Financial Health
GSK's gross margin improved sharply to 75.4% versus 69.2% a year ago, while TTM net margin stands at a healthy 17.8%. The balance sheet carries a debt-to-equity ratio of 1.08x, which is manageable, though the current ratio of 0.82x points to a tight near-term liquidity position, as current liabilities exceed current assets...
Risk Assessment
- REVENUE DECELERATION — Quarterly revenue declined 11.5% sequentially against a tepid 1.5% YoY gain, signalling a potential loss of near-term momentum.
- DEBT / LIQUIDITY — The current ratio of 0.82x is below the 1.0x threshold, indicating that current liabilities exceed liquid assets and could pressure short-term financial flexibility.
- 52-WEEK POSITION — At $50.99, the current price is 17.4% below the 52-week high of $61.70, leaving the stock well off its peak despite having recovered from the low of $35.45.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed....